• Wed news: 2025 Medicare drug price negotiations. BioAge Labs aiming at $180M IPO. Merck Keytruda colorectal cancer flop. Sanofi gets bids for consumer health unit. Novo Nordisk CEO in Senate hot seat. See more on our front page

Europe Breast team


<











Last week was a pretty tough week in Europe.

We have been told that everyone will know what will happen to them by Easter.

In some countries it might be "proposed" changes (due to labour regulations) but "proposed" and actual changes usually come out more or less the same...
 












There has been some on-off ALCL noise in the market for years, particularly among scientifically minded doctors.

At the end of the day most customers understand that their patient is probably more likely to die in a plane crash than from ALCL, so that helps put things into proper perspective.
 








While the absolute risk for ALCL is small, the risk relative to competitors is huge. A completely unnecessary risk. To my knowledge Allergan's only response to this is to come out with some really lame talking points for reps to parrot.